Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpromazine SCHEMBL8503036 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL23326209 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL5483904 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL29714121 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL41771 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL28234010 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL29367385 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL29358018 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL8321 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6LMNAMAPTHTR1A | |
| Chlorpromazine SCHEMBL27607834 | 0.97 | CYP1A2 (0.97) | CYP1A2CYP2D6LMNAMAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| EP-3426327-B1 | NEEDLELESS INJECTION DEVICE EQUIPPED WITH AN IMPROVED INJECTION NOZZLE | CROSSJECT (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4522128-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | Suntec Medical, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | SUNTEC MEDICAL INC (US) | 2025-03-06 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118420706-A | Preparation method of animal living polypeptide self-classification assembly | 南开大学 | 2024-08-02 | — | — | CN | claimed |
| US-11992660-B2 | Needleless injection device equipped with an improved injection nozzle | CROSSJECT (FR) | 2024-05-28 | — | — | US | claimed |
| US-11738151-B2 | Needleless injection device with a curved membrane | CROSSJECT (FR) | 2023-08-29 | — | — | US | claimed |
| CN-116530336-A | Prevention and treatment method for citrus yellow dragon disease of diaphorina citri | 赣南师范大学 | 2023-08-04 | — | — | CN | claimed |
| US-20230242435-A1 | METHOD FOR AIR QUENCHING AN ELONGATED GLASS HOLLOW BODY COMPRISING AN AXIAL BORE | CROSSJECT (FR) | 2023-08-03 | — | — | US | claimed |
| US-11712521-B2 | Injection nozzle for a needleless injection device | CROSSJECT (FR) | 2023-08-01 | — | — | US | claimed |
| EP-3541759-B1 | METHOD AND APPARATUS FOR AIR-QUENCHING AN ELONGATED HOLLOW GLASS BODY COMPRISING AN AXIAL BORE, ASSOCIATED PRODUCT | CROSSJECT (FR) | 2023-06-07 | — | — | EP | claimed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | claimed |
| US-20220409830-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | SIPNOSE LTD. (IL) | 2022-12-29 | — | — | US | claimed |
| WO-2022172225-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2022-08-18 | — | — | WO | claimed |
| US-11383048-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | SIPNOSE LTD. (IL) | 2022-07-12 | — | — | US | claimed |
| US-11344506-B2 | Rapidly disintegrating oral dissolvable film | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2022-05-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | DRD2 656/4885DRD3 1833/4885DRD4 2138/4885 |
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | CD14, PML, SARS1 | DRD2 4342/4885DRD3 3838/4885DRD4 3646/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | DRD2 4671/4885DRD3 4375/4885DRD4 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.